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Abstract
Background: Continuous quality improvement is fundamental in all health care, including hospice and palliative
care. Identifying and systematically reducing symptomatic adverse events is limited in hospice and palliative
care because these events are mostly attributed to disease progression.
Objectives: The aim of this study was to assess the feasibility of symptomatic adverse events in hospice and
palliative care and assessing their incidence.
Methods: A retrospective, consecutive cohort of notes from a specialist palliative care inpatient service was
surveyed by a clinical nurse consultant for symptomatic adverse events: falls, confusion, decreased conscious-
ness, hypo- and hyperglycaemia, urinary retention, and hypotension. Demographic and clinical factors were
explored for people at higher risk.
Results: Data were available on the most recent admissions of 65 people, generating >900 inpatient days. Fifty
people (78%) had events precipitating admission, of whom 31 (62%) had at least one further event during
admission. Eleven of 15 people who were admitted without an event experienced at least one during their
admissions. Only 4 did not have an adverse event. During their stay, there were 0.13 (standard deviation
[SD]¼ 0.19) events per patient per day. No drug-drug or drug-host events were noted. No clinical or demo-
graphic factors predicted groups at higher risk.
Conclusions: This pilot highlights the feasibility of collecting, and ubiquity of, symptomatic adverse events, and
forms a baseline against which future interventions to decrease the frequency or intensity can be measured.
Given the frailty of hospice and palliative patients, any adverse event is likely to accelerate irreversibly their
systemic decline.
Introduction
Minimizing suffering is a key role espoused by hospiceand palliative care services. Some suffering will be
iatrogenic. Avoiding harm is a critical concern given that any
deterioration is likely to cause at least some degree of irre-
versible deterioration in this population given people’s frailty.
On average in inpatient care, there is more than one medica-
tion error per patient per day.1 Inpatient and community
hospice and palliative care services are unlikely to have rates
that are lower given that medications for symptom control are
often simply added to medications for long-term comorbid
diseases,2 leading at times to futile or inappropriate pre-
scribing.3,4 A previous report from this setting documented an
average of five medications per person in hospice and palli-
ative care for symptom control and comorbid disease man-
agement, peaking at more than seven regular medications in
the days before death.2 Given this number of medications, it
would be expected that drug-drug and drug-host interac-
tions5 are frequently seen in the hospice and palliative care
populations—a key, predictable cause of symptomatic ad-
verse events. This may be magnified by the widespread ‘‘off-
licence’’ prescribing in hospice and palliative care.6 Individual
therapies that may cause harm include medications that may
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cause prolonged QT interval or gastrointestinal bleeding, or
parenteral fluids that may cause pulmonary edema. Estimates
suggest that medication-related events are under-reported in
hospice and palliative care, but occur frequently.7–9
A focus for quality improvement in health care is the
identification and prevention of adverse events,10 yet such
documentation is not as frequent in hospice and palliative
care as in other clinical settings. Progressive frailty, organ
dysfunction, weight loss altering drug distribution, and
polypharmacy puts the hospice and palliative population at
higher risk of symptomatic adverse events. The rates of
symptomatic adverse events, their impact on symptom con-
trol and overall patient function, and whether they could be
more systematically avoided are unknown. Actively moni-
toring for such events becomes important if their likelihood is
high, their consequences cause irreversible deterioration, or
both, as in hospice and palliative care.
The need for a definition of symptomatic adverse events
tailored to palliative care may make reporting easier and
allow a composite measure to assess and monitor them. An
adverse event in health is defined as an undesirable or un-
intended occurrence subsequent to a clinical intervention,
and may indicate that a person has received poor-quality
health care.11 Such events, many of which are avoidable, do
or could cause morbidity or premature death.10,12,13 The Joint
Commission on Accreditation of Healthcare Organizations’
view is that these events should also be discussed explicitly
with patients and their families.14 In the hospice and palli-
ative setting, the authors suggest that defining an adverse
event should include that the occurrence renders symp-
toms, distress, or irreversible deterioration for the patient.
This distinguishes symptomatic adverse events from disease
progression of advancing disease. Using this definition, iat-
rogenic renal dysfunction would not be coded from labora-
tory results unless it also caused directly attributable
symptoms.
There have been frameworks proposed to codify the pre-
ventive strategies being employed in managing active co-
morbid illnesses by incorporating: other associated risk
factors that should influence the decision making, the prog-
nosis of the person concerned, and the likely onset of conse-
quences by reducing or ceasing medications.15–17 Ceasing or
reducing therapy for active comorbidities too early or too late
may have dire consequences for the patient. For example, if
someone has poorly controlled hypertension despite an ag-
gressive antihypertensive regime on a background of two
previous cerebrovascular accidents (tertiary prevention),
ceasing this person’s antihypertensives would risk a further
cerebrovascular event thus increasing the likelihood that such
medications should be continued into the terminal phase.17 By
contrast, for secondary prevention, if an antihypertensive
medication is continued unmonitored while the person loses
weight from disseminated cancer, this may lead to hypoten-
sion thus increasing the risks of falls with potential conse-
quences including fractures or a subdural hematoma. Systems
to identify rates and subsequent impacts of symptomatic
adverse events (which may easily be attributed to disease
progression) in hospice and palliative care are needed, as in
all health care. Finding ways of monitoring and under-
standing contributing factors, and reducing the risk of iatro-
genic events, is an urgent priority in hospice and palliative
care.
The aim of this retrospective, consecutive, cohort, pilot
study is to assess the feasibility of collecting patient-defined,
symptomatic adverse events and to quantify the frequency
with which people experience these at the end of life. This
baseline rate would allow assessment of interventions to re-
duce the number or severity of events, or both.
Methods
Study setting
Australian health care provides universal insurance that
can be supplemented by private insurance and patient co-
payments. Southern Adelaide Palliative Services is a specialist
metropolitan palliative care program that provides inpatient
care, community and outpatient visits, nursing home and
hospital consultations, complementary care, and bereave-
ment services. It serves a population of 350,000 people over
an area of more than 750 km2 in public and private sectors.
The service receives more than 1100 referrals per year. The
inpatient unit provides direct specialist care and has ap-
proximately 330 admissions of 280 patients annually.
Study design and participants
A consecutive cohort of case notes for the most recent ad-
mission for 70 people was audited. The inclusion criterion
was every inpatient under the direct care of the service in a
4 month period at the end of 2008.
Data collection
Case notes including medication charts and mandatory
hospital-wide incident-reporting documents were surveyed.
A subset of symptomatic events frequently encountered in
hospice and palliative care were sought including: urinary
retention or incontinence; constipation, diarrhea or fecal im-
paction; acute confusion, poor concentration, or unexpected
decrease in level of consciousness; hypo- or hyperglycemia;
symptomatic renal or hepatic failure; symptomatic hypo- or
hypertension; and decrease mobility or falls (Table 1). These
were chosen on the grounds that they were symptomatic
for the patient and a fraction of them may be directly related
to clinical management including polypharmacy (over- or
under-treatment of comorbid diseases) or total anticholinergic
load.18 A composite measure for a crude event rate was cre-
ated by looking at the sum of all events divided by the total
number of inpatient days for all of the admissions. Only
symptomatic adverse events were included, with the excep-
tion of acute confusion or unexpected deterioration in level of
consciousness where the observations of others were ac-
cepted. An experienced clinical nurse consultant reviewed
each file for coding.
Data analysis
Descriptive data are presented. Using w2 (or Fisher’s exact
test as appropriate) dichotomous relationships were explored
between demographic and clinical factors (including age, di-
agnosis, gender, and vital status at end of admission) and
symptomatic adverse events. Data were analysed in PWAS
(SPSS Corp. Inc., Chicago, IL). Means were compared using t
tests having established that equal variances could be as-
sumed by using Levene’s test for equality of variances.
310 CURROW ET AL.
Archived at Flinders University: dspace.flinders.edu.au
Results
Of the 70 consecutive, most recent admissions requested for
review, one was inadvertently a duplicate, and the physical
medical records of another 4 people were not available,
leaving 65 evaluable patients. There were 41 males (63%) and
59 people had cancer (91%). The age of people was a mean of
69.4 years (standard deviation [SD] 14.2; range 23–93; median
70). Forty-three people (66%) died during this admission.
Average length of stay was 14.3 days (SD 15.2; median 7;
range 0–65).
From the defined events (Table 1), 50 patients (78%) had
symptomatic events precipitating admission, and of these, 31
of 50 (62%) went on to have further symptomatic adverse
events arising during the admission, none of which was
reported through the hospital’s incident reporting process
(Table 2; Fig. 1). For the 15 patients (23%) without symp-
tomatic adverse events on admission, 11 of 15 (73%) had
symptomatic events during the admission. Only 4 people
(6%) had no symptomatic adverse events on or during the
admission (Table 3).
The mean number of symptomatic adverse events noted
per person on admission was 1.14 (SD 0.88; median 1.0; range
0–3). During admission, the mean number of events per per-
son was 1.50 (SD 1.42; median 1.0; range 0–5).
Length of inpatient stay was then calculated and the
crude event rate (number of events per patient per day) was
calculated. There was a mean of 0.13 events per day (SD 0.19;
median 0.06; range 0–0.51) across this cohort, not including
events noted at the time of admission. This equates to an av-
erage of one such event per person every 7.7 days of inpatient
care.
There were no significant differences between any demo-
graphic or clinical factors and the number of events at the
time of admission or subsequently during the admission
(Table 4).
Table 1. Adverse Events on and during Admission of a Consecutive Cohort of People












Drug -drug interactions 0 0 0
Adverse drug reactions 7a 19a 4b
Worsening of preexisting comorbid condition 2 3 1
Worsening symptom control 33 20 2d
Micturition
Urinary retention 1 10 1
Urinary incontinence 5 21 6
Lower GIT
Constipation 2 7 1
Diarrhea 3 8 0
Fecal impaction 2 4 1
CNS
Acute confusional state 6 22 6
Poor concentration 0 1 0
Decreased level of consciousness 3 20 0
Metabolic
Hypoglycemia 0 1 0
Hyperglyaemia 2 1 1
Renal failure 2 4 1
Hepatic failure 8 1 1
Circulatory
Hypotension 0 1 1
Hypertension 1 0 0
Decreased mobility 10e 12 6
Falls 7f 8c 0
aOnly 4 due to medications for comorbid conditions including atenolol causing severe symptomatic hypotension, digoxin toxicity,
frusemide causing severe hyperkalemia, and a cutaneous medication reaction to vancomycin. All other adverse events were due to
medications for symptom control (predominantly opioids (n¼ 13; 5 on admission, 8 during admission) and dexamethasone (n¼ 6; 3 on
admission and 3 during admission).
bFour people with adverse events at the time of this admission went on to have adverse events with other classes of medications during the
admission.
cFour people had multiple falls documented.
dFor the same symptom on both occasions.
eTwo people have had spinal cord compression—a suggested ‘‘sentinel event.’’
fOne person had multiple falls documented.
CNS, central nervous system; GIT, gastro-intestinal.
Table 2 Number of Patients with Frequency







0 15 (23) 22 (34)
1 32 (49) 14 (22)
2 12 (19) 13 (20)
3 6 (9) 11 (17)
4 – 4 (6)
5 – 1 (1)
ADVERSE EVENTS IN HOSPICE AND PALLIATIVE CARE 311
Archived at Flinders University: dspace.flinders.edu.au
Discussion
Only 4 patients in this study did not have a symptomatic
adverse event (an undesirable and unintended occurrence),
underscoring the importance of monitoring and evaluating
such events in this population for preventable harm. Given
the reduced physiological reserve of the hospice and palliative
care population, any insult (a fall, an episode of severe hy-
poglycaemia) has the potential to irreversibly limit indepen-
dence, especially if function is already compromised.19,20 A
recent, large, cohort confirmed that a sudden drop in perfor-
mance status led to the person’s prognosis most closely re-
flecting the performance status after the drop. Although
symptomatic adverse events are often the reason for presen-
tation, 65% of patients developed events during admission,
with 45% having more than one subsequent event.
Events that impact on people’s mobility, confidence (pa-
tient and caregiver), or independence appear from this study
to be ubiquitous in the hospice and palliative care population,
with 94% of people having such an event leading to or in their
most recent admission. This study has not demonstrated a
particular group defined by age, gender, or diagnosis as
having increased events, suggesting that every hospice and
palliative care inpatient is at risk and should be a focus for
reducing the frequency and severity of such events. By cre-
ating a crude event rate similar to the Institutes of Medicine
medication error rate, it is possible to plan prospective studies
that could evaluate interventions specifically designed to re-
duce such events.1
A proportion of these events may be iatrogenic especially
due to the unnecessary continuation or early cessation of
medications for comorbid illnesses at the end of life or med-
ications for symptom control.21 Although it is not possible to
attribute many such events to one factor, prescribing for co-
morbid illnesses is a modifiable factor that can reduce such
risks. Therefore, it would be possible to compare an inter-
vention group that had a careful medication review with
a control group offered current practice.22,23 Using patient-
defined event rates as a surrogate for improved prescribing
would allow empiric testing of a structured model of ratio-
nalizing medications for comorbid diseases at the end of life in
a structured way and would define whether this translates
into improved patient outcomes.4
Given the prescribing patterns in hospice and palliative
care, it is of note that no drug-drug interactions were docu-
mented in this cohort. Likewise, no medication errors were
documented despite an aggregate measure (similar to the
crude event rate used in this article) estimating one event per
patient per inpatient day.1 Factors contributing to this may
include under-recognition, lack of documentation, or mis-
attribution of the event to disease progression. Statistically, it
would be almost impossible for the more than 900 consecutive
patient days of inpatient care reported here to have had no
such events.1,24,25
A specific subgroup of adverse events are sentinel events
(Table 1). These are defined as ‘‘an unexpected occurrence
involving death or serious physical or psychological injury, or
risk thereof.’’11 In hospice and palliative care, sentinel events
to consider include spinal cord compression (especially if
there are preceding symptoms or signs that were missed or
not acted on), significant proximal myopathy as a result of
long-term glucocorticoids, and falls that result in serious in-
jury or death. Palliative care and hospice services need to have
systems in place to systematically record sentinel events and
analyse contributing factors that are modifiable rather than
attribute these events uncritically to progressive underlying
disease, given their recently reported frequency.20
Limitations
This is a retrospective case note review and therefore only
captures events and their symptom complexes that were
documented in the clinical notes; hence the estimates may be
under-reporting actual events, especially given the propensity
to attribute changes in clinical condition in hospice and pal-
liative care to disease progression. The threshold for the se-
verity of events to be documented and reported is unlikely to
be standardized across the whole group of practitioners. Falls
for example are more likely to be noticed and reported than
hypoactive delirium. The list of ‘‘events’’ was arbitrary, but
aimed to cover most of the frequently encountered issues that
may have an iatrogenic component or contribute to functional
decline.
The severity of events or reversibility was not graded in the
data collection. Future work can help to estimate the severity
and the proportion that was avoidable or reversible without
loss of function. Association of adverse clinical outcomes that
may appear much later after such an event (a subsequent deep
FIG 1. Cumulative number of sentinel events that may be
related to prescribing (n¼ 70).
Table 3. Number of Patients with Events
on Admission Matched to Events
during Admission (percentage of total
[n¼ 65] in brackets)
Events during admission
Yes No
Events noted at the
time of admission
Yes 31 (48) 19 (29)
No 11 (17) 4 (6)
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vein thrombosis after a much earlier fall causing a fractured
neck of femur; cessation of long-term anticoagulation for at-
rial fibrillation and subsequent cerebrovascular accident) was
not possible. The timing of each symptomatic adverse event in
relation to the date of admission was not tabulated, but could
strengthen future work.
Generalizability
This study is from one inpatient unit. The rates quoted may
vary between services with differing length of inpatient stays,
demographics of patients referred (especially average age
given the relationship to increasing comorbid illness with
age), time from referral to death, and the diagnoses of those
referred to a service.
Implications for research
Comparing and contrasting these event rates prospectively
with a community cohort will help to understand the fre-
quency and severity of such events across the whole hospice
and palliative care population. The severity of events needs to
be systematically graded in the future. The clinical response
(speed of recognition, response to reversible causes) to each
event also needs to be codified in prospective data collection
as well as when each incident event occurs in relation to date
of inpatient admission.
A key challenge is, having had an event, what has been
done to prevent a recurrence? It is understandable that, de-
spite optimal management, patients will have symptomatic
adverse events, but how can they be minimized? One episode
of hypoglycemia may be acceptable, but repeated episodes
rapidly call into question the clinical management offered to
this person.
The frequency of events noted in this study suggests an
urgent need to evaluate systematic methods for guiding
clinical decision making in prescribing for primary and sec-
ondary prevention in inactive comorbid disease. Ultimately,
as one strategy, could iatrogenic morbidity and mortality be
minimized by adopting a systematic approach to the evalu-
ation of each comorbid illness for each dying person?
Implications for practice
These data present a high baseline event rate of symp-
tomatic adverse events in a hospice and palliative care
population. It is certain that almost all such events in hospice
and palliative care practice are multifactorial and attribution
is difficult. The first step in dealing with symptomatic ad-
verse events is to obtain consensus on their definition, at-
tribution, and importance in hospice and palliative care
and monitor their impact on functional status prospec-
tively in the way that Downing and colleagues have recently
described.20
Can the number of events be decreased or lessened in se-
verity? Contributing factors that are not directly modifiable
include the global deterioration associated with late-stage life-
limiting illnesses. How many symptomatic adverse events are
iatrogenic either from less than optimal management of co-
morbid conditions as functional and metabolic status wors-
ens, or from symptom control initiatives that, at times, are
having a net detriment on the patient?26
These data suggest that no specific patient profile allows us
to target people a priori. These events are ubiquitous given the
frail and progressively worsening function of the population,
but rates may be modified.
At the very least, the checklist may form a baseline for
regular hospice and palliative care morbidity meetings. Also
included should be hospice and palliative care–specific sen-
tinel events including spinal cord compression, steroid in-
duced myopathy, or sudden death in the setting of a high
functional status ante mortem.
Conclusions
These data demonstrate that it is feasible to identify symp-
tomatic adverse events in the hospice and palliative care pop-
ulation and, given the frequency with which they occur, that
every effort should be made to measure them routinely and
systematically. These data provide a baseline against which
future work can be compared and the definition and metric of
symptomatic adverse events in hospice and palliative care can
be developed and refined. As clinicians, if we regard these
events as simply another inevitable outcome of worsening
disease, we will continue to preclude the possibility of sys-
tematically reducing the risks of such events, some of which are
likely to be iatrogenic. Such reduction in rates is likely to be able
to be achieved without worsening symptom control.
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